ArticleBMJ global health2019
Cost-effectiveness of community-based screening and treatment of moderate acute malnutrition in Mali.
Article in BMJ global health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01015950 (Randomized, Community-Based Effectiveness Trial of Selected Dietary Strategies for the Management of Young Malian Children With Moderate Acute Malnutrition), which is not on this map. Cited by 33 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized, Community-Based Effectiveness Trial of Selected Dietary Strategies for the Management of Young Malian Children With Moderate Acute Malnutrition (MAM) in the Context of the National Community Management of Acute Malnutrition
Who cites it
33 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Local Food Interventions for the Management of Moderate Acute Malnutrition (MAM) among Children Aged 6 to 59 Months: A Systematic Review and Non-inferiority Meta-Analysis.Advances in nutrition (Bethesda, Md.) · 2026Pooled it
- Systematic Review of Management of Moderate Wasting in Children over 6 Months of Age.Nutrients · 2023Pooled it
- Pooled it
- Measurement of benefits in economic evaluations of nutrition interventions in low- and middle-income countries: A systematic review.Maternal & child nutrition · 2022Pooled it
- Economic Evaluations of Child Nutrition Interventions in Low- and Middle-Income Countries: Systematic Review and Quality Appraisal.Advances in nutrition (Bethesda, Md.) · 2022Pooled it
- Pooled it
- Cost and cost-effectiveness analysis of treatment for child undernutrition in low- and middle-income countries: A systematic review.Wellcome open research · 2020Pooled it
- Cost-effectiveness of decentralising acute malnutrition treatment with a standard or simplified treatment protocol: an economic evaluation in the region of Gao, Mali.BMC public health · 2025Trial
- Trial
- Efficacy of ready-to-use food supplement for treatment of moderate acute malnutrition among children aged 6 to 59 months.Maternal & child nutrition · 2024Trial
- Effectiveness of decentralizing outpatient acute malnutrition treatment with community health workers and a simplified combined protocol: a cluster randomized controlled trial in emergency settings of Mali.Frontiers in public health · 2024Trial
- Estimating the impact and cost-effectiveness of antenatal care approaches in 24 low- and middle-income countries: a modelling study.BMC global and public health · 2026Article
- Costs and benefits of replacing preventive antenatal iron and folic acid with multiple micronutrients in 25 low- and middle-income countries.BMJ global health · 2026Article
- Genome-wide association study of seed mineral nutrients in peas (Pisum sativum L.).The plant genome · 2025Article
- The Cost of Managing Moderate Wasting Using Local Foods: Evidence from Three Interventions in Northeast Nigeria.Public health nutrition · 2025Article
- Dietary outcomes of moderately wasted children treated in a food voucher program in Cameroon's Far North: a three-month longitudinal study.BMC nutrition · 2025Article
- Article
- Treatment of moderate acute malnutrition through community health volunteers is a cost-effective intervention: Evidence from a resource-limited setting.Maternal & child nutrition · 2024Article
- Evidence on the impact of community health workers in the prevention, identification, and management of undernutrition amongst children under the age of five in conflict-affected or fragile settings: a systematic literature review.Conflict and health · 2024Review
- Impact of COVID-19 program adaptations on costs and cost-effectiveness of community management of acute malnutrition program in South Sudan.Public health nutrition · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionModerate acute malnutrition (MAM) causes substantial child morbidity and mortality, accounting for 4.4% of deaths and 6.0% of disability-adjusted life years (DALY) lost among children under 5 each year. There is growing consensus on the need to provide appropriate treatment of MAM, both to reduce associated morbidity and mortality and to halt its progression to severe acute malnutrition. We estimated health outcomes, costs and cost-effectiveness of four dietary supplements for MAM treatment in children 6-35 months of age in Mali.
methodsWe conducted a cluster-randomised MAM treatment trial to describe nutritional outcomes of four dietary supplements for the management of MAM: ready-to-use supplementary foods (RUSF; PlumpySup); a specially formulated corn-soy blend (CSB) containing dehulled soybean flour, maize flour, dried skimmed milk, soy oil and a micronutrient pre-mix (CSB++; Super Cereal Plus); Misola, a locally produced, micronutrient-fortified, cereal-legume blend (MI); and locally milled flour (LMF), a mixture of millet, beans, oil and sugar, with a separate micronutrient powder. We used a decision tree model to estimate long-term outcomes and calculated incremental cost-effectiveness ratios (ICERs) comparing the health and economic outcomes of each strategy.
resultsCompared to no MAM treatment, MAM treatment with RUSF, CSB++, MI and LMF reduced the risk of death by 15.4%, 12.7%, 11.9% and 10.3%, respectively. The ICER was US$9821 per death averted (2015 USD) and US$347 per DALY averted for RUSF compared with no MAM treatment.
conclusionMAM treatment with RUSF is cost-effective across a wide range of willingness-to-pay thresholds.
trial registrationNCT01015950.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.